https://www.medimergent.com/company/leadership/
See above link for a highly interesteing bio of Dr. Kenneth Borow, holder of multiple patents, and co-patent applicant of SI for the method of treating progressive HF patients at high risk of poor outcomes. He is the Chief Medical Officer of MediMergent, clinician and heart failure expert at The University of Chicago (and previously Harvard Medical School). Read till the end and you will notice he has expertise in biomarkers and to add to that, he was the CEO of a NASDAQ traded CRO from 2000. He also has substantial experience with designing clinical trials and involvement with both the FDA and EMA.
Medimergent seems like a tech/data company:
https://www.medimergent.com/
Cell Therapy News/Articles, page-17486
-
- There are more pages in this discussion • 297 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.8¢ |
Change
-0.038(3.66%) |
Mkt cap ! $1.127B | |||
| Open | High | Low | Value | Volume |
| $1.03 | $1.04 | 97.0¢ | $6.056M | 6.039M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 27957 | 98.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.0¢ | 100018 | 26 |
View Market Depth
| Last trade - 14.05pm 24/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |